Report cover image

Acquired Gene or Chromosome Alterations Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2023 Update

Publisher GlobalData
Published Dec 19, 2023
Length 281 Pages
SKU # GBDT18459006

Description

Acquired Gene or Chromosome Alterations Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2023 Update


Summary

GlobalData's Medical Devices sector report, “Acquired Gene or Chromosome Alterations Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2023 Update provides comprehensive information about the Acquired Gene or Chromosome Alterations pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

Acquired Gene or Chromosome Alterations comprises of reagents employed for genetic testing to detect cancer causing/ related alterations, such as; k-ras, BRCA 1+2, Telomerase and HER-2/neu (human epidermal growth factor receptor 2).

Note:Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope
  • Extensive coverage of the Acquired Gene or Chromosome Alterations under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Acquired Gene or Chromosome Alterations and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry
Reasons to Buy

The report enables you to -
  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
  • Identify and understand important and diverse types of Acquired Gene or Chromosome Alterations under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory and estimated launch date

Table of Contents

281 Pages
  • About GlobalData
    • Acquired Gene or Chromosome Alterations Overview
    • Acquired Gene or Chromosome Alterations - Pipeline Products by Stage of Development
    • Acquired Gene or Chromosome Alterations - Pipeline Products by Territory
    • Acquired Gene or Chromosome Alterations - Pipeline Products by Regulatory Path
    • Acquired Gene or Chromosome Alterations - Pipeline Products by Estimated Approval Date
    • Acquired Gene or Chromosome Alterations - Ongoing Clinical Trials
    • Acquired Gene or Chromosome Alterations Companies - Pipeline Products by Stage of Development
    • Acquired Gene or Chromosome Alterations – Companies Pipeline Products by Stage of Development
    • Abital Pharma Pipelines Ltd Company Overview
    • Admera Health LLC Company Overview
    • Agena Bioscience Inc Company Overview
    • Aix-Marseille University Company Overview
    • Albert Ludwigs University of Freiburg Company Overview
    • Apteryx Imaging Inc Company Overview
    • Baruch S. Blumberg Institute Company Overview
    • Baylor College of Medicine Company Overview
    • bioMerieux SA Company Overview
    • Biotype Innovation GmbH Company Overview
    • Blondin Bioscience, LLC Company Overview
    • Cardiff Oncology Inc Company Overview
    • Cepheid Inc Company Overview
    • Children's Hospital Los Angeles Company Overview
    • Children's Hospital of Philadelphia Company Overview
    • China Medical Technologies Inc (Inactive) Company Overview
    • Chronix Biomedical Inc Company Overview
    • Columbia University Company Overview
    • Duke University Company Overview
    • Empire Genomics LLC Company Overview
    • Fred Hutchinson Cancer Research Center Company Overview
    • French National Institute of Health and Medical Research Company Overview
    • Garvan Institute of Medical Research Company Overview
    • Gencurix Inc Company Overview
    • Genetag Technology, Inc Company Overview
    • Genomic Health Inc Company Overview
    • GenomicTree Co Ltd Company Overview
    • German Cancer Research Center Company Overview
    • H. Lee Moffitt Cancer Center & Research Institute Inc Company Overview
    • Heali Ltd Company Overview
    • Hebrew University of Jerusalem Company Overview
    • Heidelberg Pharma AG Company Overview
    • Helmholtz Centre for Infection Research Company Overview
    • Inform Genomics Inc Company Overview
    • Institute of Cancer Research Company Overview
    • Interpace Biosciences Inc Company Overview
    • iTP Biomedica Corp Company Overview
    • Johns Hopkins University Company Overview
    • Massachusetts General Hospital Company Overview
    • Mayo Clinic Company Overview
    • McGill University Company Overview
    • MDNA Life Sciences Inc Company Overview
    • MolecularMD Corp Company Overview
    • Myriad International GmbH Company Overview
    • Nel ASA Company Overview
    • Northern California Institute for Research and Education Company Overview
    • NucleoBio Inc Company Overview
    • Ohio State University Company Overview
    • OmicsWay Corp Company Overview
    • Oxford Biodynamics Plc Company Overview
    • Oxford Cancer Biomarkers Ltd Company Overview
    • Pennsylvania State University Company Overview
    • Princess Margaret Cancer Centre Company Overview
    • QuantuMDx Group Ltd Company Overview
    • Queen's University Belfast Company Overview
    • Rosetta Genomics Ltd (Inactive) Company Overview
    • Stanford University Company Overview
    • Stony Brook University Company Overview
    • Syamala Srinivasa Life Sciences Pvt. Ltd Company Overview
    • Telo Genomics Corp Company Overview
    • The Chinese University of Hong Kong Company Overview
    • The University of New South Wales press Limited Company Overview
    • The Walter and Eliza Hall Institute of Medical Research Company Overview
    • TheraDiag SA Company Overview
    • Therawis Diagnostics GmbH Company Overview
    • Thrive Earlier Detection Corp Company Overview
    • Total Brain Ltd Company Overview
    • Trinity College Dublin Company Overview
    • University College London Company Overview
    • University of California San Diego Company Overview
    • University of Cambridge Company Overview
    • University of Central Florida Company Overview
    • University of Cologne Company Overview
    • University of Copenhagen Company Overview
    • University of Hawaii at Manoa Company Overview
    • University of Montreal Company Overview
    • University of Rochester Company Overview
    • University of South Carolina Company Overview
    • University of Southern California Company Overview
    • University of Strathclyde Company Overview
    • University of Sydney Company Overview
    • University of Texas Medical Branch at Galveston Company Overview
    • University of Washington Company Overview
    • Vyant Bio Inc Company Overview
    • Wistar Institute Company Overview
    • Yaathum Biotech Pvt Ltd Company Overview
    • Yale University Company Overview
    • Dec 13, 2023: Pfizer Provides Full-Year 2024 Guidance
    • Dec 12, 2023: Genentech Announces Appointment of Ashley Magargee as Chief Executive Officer
    • Dec 10, 2023: MGI Expands Presence in Latin America with New Partnerships with Genos Médica and TCL Group
    • Nov 20, 2023: Labcorp and Legacy Health Finalize Comprehensive Laboratory Relationship
    • Nov 14, 2023: Genomic Vision: Financial Information for the Third Quarter of 2023
    • Nov 07, 2023: SOPHiA GENETICS Reports Financial Results for the Third Quarter of Fiscal 2023 Record results on growth acceleration, significant improvement in operating loss and cash burn
    • Nov 03, 2023: Castle Announces Early Exploratory Study Data for Potential Development of a Complementary Test to Accompany DecisionDx-UM That Could Aid in the Early Detection of Uveal Melanomas
    • Nov 02, 2023: Celldex Reports Third Quarter 2023 Financial Results and Provides Corporate Update
    • Oct 31, 2023: Amgen Reports Third Quarter Financial Results
    • Oct 28, 2023: Pfizer Q2 Results: Drug Maker's Profit Declines 52% To Rs 149 Crore
    • Oct 27, 2023: ORYZON Reports Financial Results and Corporate Updates for Quarter Ended September 30, 2023
    • Oct 26, 2023: Labcorp Announces 2023 Third Quarter Results
    • Oct 26, 2023: Lilly to Participate in UBS Biopharma Conference 2023
    • Oct 20, 2023: Lilly Confirms Date and Conference Call for Third-Quarter 2023 Financial Results Announcement
    • Oct 19, 2023: bioMérieux Makes Strategic Investment in Oxford Nanopore
    • Oct 06, 2023: Children's Mercy Kansas City First to Use 5-Base HiFi Genomic Sequencing in the Clinical Setting
    • Oct 05, 2023: Illumina to Announce Third Quarter 2023 Financial Results on Thursday, November 9, 2023
    • Oct 04, 2023: Lilly Announces Leadership Transitions
    • Oct 04, 2023: AbbVie to Host Third-Quarter 2023 Earnings Conference Call
    • Sep 29, 2023: Genomic Vision: First-Half 2023 Results
    • Sep 28, 2023: Pfizer Appoints New Chief IR Officer
    • Sep 27, 2023: Mdxhealth Signs Research Collaboration with University of Oxford to Assess the Correlation of the GPS Test with Prostate Cancer Progression Following Treatment for Localized Prostate Cancer
    • Sep 14, 2023: Labcorp to Present Strategy, Business and Financial Outlook at Investor Day
    • Sep 07, 2023: Veracyte Names Marie-Claire Taine, Ph.D., as General Manager of Its IVD Business Unit To Advance Global Expansion of the Company's Tests
    • Sep 05, 2023: Illumina's Board Appoints Jacob Thaysen, Ph.D. as its New Chief Executive Officer
    • Aug 28, 2023: Novartis to Let Go 100 Employees in Latest Round of Layoffs
    • Aug 17, 2023: Myriad Genetics to Host Investor Day on September 19, 2023
    • Aug 17, 2023: Illumina Expands Genomics Capabilities in India with Opening of Solutions Center
    • Aug 17, 2023: Illumina Announces Lays Off 151 San Diego workers
    • Aug 13, 2023: Illumina Announces Departure of Chief Medical Officer and Chief Technology Officer
    • Aug 09, 2023: Cigna Expands Commercial and Medicare Advantage Coverage to Include Mdxhealth's Select mdx for Prostate Cancer Test
    • Aug 09, 2023: Interpace Biosciences Announces Record Second Quarter 2023 Financial and Business Results
    • Aug 09, 2023: Cardiff Oncology Reports Second Quarter 2023 Results and Provides Business Update
    • Aug 09, 2023: Dr. Steven Barnard Appointed Chief Technology Officer
    • Aug 08, 2023: Celldex Reports Second Quarter 2023 Financial Results and Provides Corporate Update
    • Aug 01, 2023: Astellas Pharma Announces Results for the First Three Months of FY2023
    • Jul 31, 2023: Labcorp to Host Investor Day on September 14, 2023
    • Jul 10, 2023: Interpace Biosciences Releases Preliminary Record Second Quarter 2023 Business Results; Updates Status of PancraGEN Reimbursement
    • Jul 03, 2023: Pacific Edge Updates Billing Policies for US Testing
    • Jun 30, 2023: Centogene Announces Approval of All Resolutions Tabled at 2023 Annual General Meeting
    • Jun 29, 2023: NeoGenomics Expands Board of Directors with Appointments of Three Independent Directors
    • Jun 27, 2023: bioMErieux's Executive Committee evolves: Jennifer Zinn appointed Executive Vice President of Clinical Operations
    • Jun 15, 2023: Amgen lures Moderna Exec to be its Chief Medical Officer
    • Jun 07, 2023: Genomic Vision Provides Strategy Update
    • Jun 05, 2023: Biocartis Announces Resignation CFO
    • Jun 03, 2023: Castle Biosciences to share new data on DecisionDx(R)
    • Jun 02, 2023: Illumina's Board of Directors elects two experienced Independent Directors to Board
    • Jun 02, 2023: Agilent Intelligent Mass Spectrometry Solutions to Inspire at ASMS 2023
    • May 29, 2023: Invivoscribe receives updated reimbursement for LeukoStrat assay in Japan
    • May 16, 2023: CENTOGENE reports full year 2022 financial results
    • May 16, 2023: Oxford BioDynamics notice of interim results and investor webinar
    • May 12, 2023: Invivoscribe's LeukoStrat assay receives IVDR approval
    • May 12, 2023: Biocartis Group announces results of the annual shareholders meeting held on 12 May 2023
    • May 09, 2023: Natera reports first quarter 2023 financial results
    • May 08, 2023: NeoGenomics reports first quarter 2023 results
    • May 04, 2023: Celldex reports First Quarter 2023 financial results and provides corporate update
    • May 04, 2023: Cardiff Oncology reports first-quarter 2023 results and provides business update
    • May 03, 2023: Myriad Genetics reports first quarter 2023 financial results
    • Apr 27, 2023: AMGEN reports first quarter financial results
    • Apr 27, 2023: Veracyte announces five abstracts providing molecular insights into prostate and other cancers to be presented at the 2023 ASCO Annual Meeting
    • Apr 25, 2023: Illumina reports financial results for first quarter of fiscal year 2023; announces commitment to accelerate margin growth
    • Apr 20, 2023: QIAGEN announces expansion of supervisory board
    • Apr 19, 2023: Foundational LCD covers select mdx for prostate cancer
    • Apr 19, 2023: Foundation Medicine lays off 135 employees
    • Apr 13, 2023: Lilly Confirms Date and Conference Call for First-Quarter 2023 Financial Results
    • Apr 11, 2023: Biocartis appoints Roger Moody as new CEO
    • Mar 31, 2023: Pacific Edge provides update on Kaiser EMR integration
    • Mar 28, 2023: EKF Diagnostics Holdings Announces its final results for the year ended 31 December 2022
    • Mar 15, 2023: Veracyte Announces Three Abstracts to Be Presented at AACR Annual Meeting 2023
    • Mar 10, 2023: GSK publishes Annual Report 2022
    • Mar 09, 2023: CENTOGENE Appoints Ian Rentsch as Chief Commercial Officer and General Manager
    • Mar 08, 2023: bioMerieux Announces 2022 Financial Results for the year ending December 31, 2022
    • Feb 28, 2023: Genomic Vision Financial Information for the Fourth Quarter of 2022
    • Feb 27, 2023: Musa Tariq Joins Guardant Health Board of Directors
    • Feb 27, 2023: Daan Gene's Prelim 2022 Net Profit Up 53.1% Y/Y
    • Feb 23, 2023: Biocartis announces 2022 results and 2023 outlook
    • Feb 23, 2023: Natera Appoints Ruth E. Williams-Brinkley to its Board of Directors
    • Feb 16, 2023: Labcorp Announces 2022 Fourth Quarter and Full-Year Results
    • Feb 16, 2023: Celldex Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors
    • Feb 13, 2023: MDxHealth announces UnitedHealthcare to provide commercial coverage for the genomic Prostate Score (GPS) Test
    • Feb 09, 2023: Sysmex Announces Summary of Consolidated Financial Results for the First Nine Months of the Fiscal Year Ending March 31, 2023
    • Feb 09, 2023: Pfizer Announces Appointment of Meenakshi Nevatia as the Managing Director
    • Feb 08, 2023: Sysmex Corp. Notice of Changes in Representative Directors
    • Feb 08, 2023: Astellas Pharma Announces Financial Results Third quarter FY2022
    • Feb 07, 2023: QIAGEN Exceeds Outlook for Fourth Quarter and Full-Year 2022 With 14% CER Sales Growth in FY 2022 From Non-COVID Product Groups
    • Feb 01, 2023: Novartis Announces Annual Report 2022
    • Feb 01, 2023: Guardant Health to Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023
    • Jan 31, 2023: Daiichi Sankyo Announces Consolidated Financial Results for the First Nine Months of the Year Ending March 31,2023
    • Jan 25, 2023: Guardant Health Lays off 7 Percent of Workforce
    • Jan 20, 2023: Quest Diagnostics to Release Fourth Quarter and Full Year 2022 Financial Results on February 2, 2023
    • Jan 19, 2023: Lilly Confirms Date and Conference Call for Fourth-Quarter 2022 Financial Results
    • Jan 19, 2023: Bioasis Announces Filing of its Quarterly Financial Statements and MD&A for the Period Ending November 30, 2022
    • Jan 17, 2023: Data presentations at 2023 Winter Clinical Dermatology Conference - Hawaii support clinical value of Castle Biosciences' skin cancer test portfolio
    • Jan 09, 2023: Guardant Health Announces Preliminary Fourth Quarter and Full Year 2022 Results
    • Dec 28, 2022: Centogene Announces Its Attendance at the 41st Annual J.P. Morgan Healthcare Meeting and Fierce JPM Week in San Francisco
    • Dec 22, 2022: CENTOGENE Reports Second Quarter and First Half 2022 Financial Results
    • Methodology
    • About GlobalData
    • Contact Us
    • Disclaimer
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.